FAP and neoplasm: FAP+ CAFs have emerged as a therapeutic paradigm for new PAAD drug candidates with the development of novel nanoparticle conjugates and antibody-conjugates, which will contribute to overcoming matrix barriers to drug delivery, thereby facilitating the rapid accumulation of immune checkpoint inhibitors at tumor sites.